Nevada Diabetes Drug Pricing Law Targeted By PhRMA/BIO Lawsuit

Law requires manufacturers to report production, marketing costs and pricing details that would be publicly released by state health department. Trade groups' lawsuit argues requirements are unconstitutional.

Diabetes-Concept_56048224_1200x675

The biopharmaceutical industry is seeking to block implementation of most of the provisions of a diabetes drug pricing transparency law in Nevada with a Sept. 1 lawsuit against Governor Brian Sandoval and Health and Human Services Department Director Richard Whitley.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access